Home » ALOXI injection receives FDA acceptance for prevention of nausea.

ALOXI injection receives FDA acceptance for prevention of nausea.

CINV is among the most common side effects following therapy in patients with tumor. ‘We are pleased with the Agency's decision to approve ALOXI in the pediatric environment, giving children with cancers another option to assist in preventing acute chemotherapy-induced vomiting and nausea,’ said Yuji Matsue, CEO and Chairman, Eisai Inc.’ Related StoriesResearch shows link between absence of RB protein and long-term survival rates in lung tumor patientsChemotherapy-induced nausea and vomiting most common distressing symptoms in majority of cancer patientsMD Anderson study reveals why chemotherapy drugs not effective for many pancreatic cancer patients’Preventing nausea and vomiting induced by chemotherapy remains an unmet need in children, despite obtainable therapies,’ said Riccardo Braglia, CEO, Helsinn Group.’ In response to a created demand from the FDA, Helsinn executed four pediatric clinical trials with ALOXI.15 mg/kg given 30 minutes prior to chemotherapy followed by infusions four and eight hours following the first dose of ondansetron.4 % of patients who received ALOXI 20 mcg/kg versus 58.6 % of these who received the ondansetron regimen.‘Following our successful acquisition of two promising compounds, our financing with Woodford provides us with the assets we need to continue to rapidly advance our clinical development applications while also positioning us to help expand broaden our pipeline. ‘We are especially pleased that the team at Woodford, a global leader in life technology investments, has acknowledged the strong potential for achievement in both our possessions and our business design at AMO Pharma.’ In early 2016, AMO Pharma programs to initiate a Phase II clinical trial for the firm's lead item candidate, AMO-02, in the treating a severe type of myotonic dystrophy known as DM1 or Steinert's disease. Myotonic dystrophy is a genetic disorder that triggers muscle and skeletal weakness and dysfunction, cognitive deficits, in addition to symptoms affecting additional organs in your body.